Accueil   Diary - News   All news NH TherAguix announces the launch of its IPO on the Euronext Growth market in Paris

NH TherAguix announces the launch of its IPO on the Euronext Growth market in Paris

 

 

NH TherAguix, a French biotechnology company specialising in the development of innovative nano medicines for the radiotherapy treatment of cancer indications, is announcing the launch of its initial public offering with a view to listing its shares on the Euronext Growth market (ISIN code: FR0013105954- ticker: ALNHT).

 

 

Géraldine Le Duc, Chief Executive Officer of NH TherAguix, says: "NH TherAguix aims to demonstrate that its candidate drug AGuIX® increases the effectiveness of radiotherapy on solid tumours, while sparing the surrounding healthy tissues. It offers new hope for cancer patients and our ambition is to make AGuIX® the new standard of care in the treatment of certain cancers with radiotherapy...".

 

 

Read the press release